Video Experimental Relacionado
Updated: Aug 23, 2026
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Enalapril en pacientes con insuficiencia cardíaca crónica: un estudio doble ciego, aleatorizado y controlado con
Circulation
|August 1, 1984
Resumen
Enalapril mejoró significativamente la capacidad de ejercicio y redujo las dimensiones del ventrículo izquierdo en pacientes con insuficiencia cardíaca congestiva durante 3 meses. Este estudio establece el enalapril.
Área de la Ciencia:
- Cardiología Cardiología.
- Farmacología Farmacología.
Sus antecedentes:
- El tratamiento de la insuficiencia cardíaca congestiva (ICF) a menudo implica inhibidores de la enzima convertidora de angiotensina.
- La eficacia a largo plazo del enalapril oral en CHF requiere más estudios controlados.
Objetivo del estudio:
- Evaluar la eficacia a largo plazo del enalapril en pacientes con insuficiencia cardíaca de la clase funcional II a III de la Asociación del Corazón de Nueva York.
Principales métodos:
- 36 pacientes clínicamente estables con CHF que recibían digoxina y diuréticos fueron asignados al azar a enalapril (5 mg dos veces al día) o placebo en un estudio doble ciego.
- Las evaluaciones incluyeron síntomas, capacidad de ejercicio, ecocardiografía y cateterismo cardíaco derecho al inicio y después de 3 meses.
Principales resultados:
- El grupo de enalapril mostró mejoras significativas en la impresión subjetiva, la clase funcional y la duración del ejercicio (p < .001).
- Enalapril redujo las dimensiones del ventrículo izquierdo y aumentó la fracción de acortamiento; el grupo placebo no mostró cambios significativos.
- Se observaron menos ajustes de la dosis diurética y muertes en el grupo de enalapril en comparación con el placebo.
Conclusiones:
- El enalapril demuestra una eficacia significativa a largo plazo en la mejora de los síntomas y la función cardíaca en pacientes con insuficiencia cardíaca congestiva.
- Enalapril ofrece una opción terapéutica prometedora para el manejo de la insuficiencia cardíaca congestiva.
Videos de Conceptos Relacionados
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.